Foundayo's fourth-week IQVIA print lands Friday or Saturday into the U.S. tape. RBC Capital Markets analyst Trung Huynh has set the bar in the open: "By week 12, we would expect Foundayo to reach more than 90,000 weekly prescriptions to remain on track for average annual sales expectations of about $1.4 billion." [1] Yesterday's paper carried Foundayo's week three at 5,612 fills against the Wegovy pill's 134,000 the same week — a 24x gap. Week four is the first read on whether the trajectory compresses or holds.

The math is unforgiving. To reach 90,000 weekly scripts by week 12, Foundayo needs to roughly double its weekly run-rate every two weeks for eight weeks — an exponential ramp with no historical analog in oral GLP-1 launches. Novo Nordisk's pill cleared 18,410 prescriptions in its first full week, then scaled to 113,000 by week 13 and 207,000 by April 17. [2] Wegovy oral entered a market with pent-up demand for the first oral GLP-1; by Foundayo's April 9 broad launch, that cohort had largely converted. Lilly executives told analysts April 30 that 20,000 patients have been treated, with 8,000 prescribers — a third new to oral GLP-1s. [3]

The architectural drag is structural. Foundayo requires a fasting window before eating; oral semaglutide does not. Wegovy carries TrumpRx self-pay coverage at announced $25 and $149 tiers; Foundayo had not appeared on the federal portal as of last week. Two of the three largest pharmacy benefit managers have commercial coverage in place; the third has not. [4] BioPharma Dive's running framing — "shaky week" — captures the analyst register. If Friday's print clears 12,000, the 24x gap compresses meaningfully. If it stays under 8,000, the FY $1.4 billion model needs revision before Q2 close. The chart, not the press release, is the call.

-- NORA WHITFIELD, Chicago